SEP
INDV icon

Signature Equity Partners’s Indivior Pharmaceuticals INDV Stock Holding History

Signature Equity Partners’s Portfolio INDV Stock Details INDV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$328 Hold
8
– – ﹤0.01% 1465
2026
Q1 		$244 Buy
8
+5
+167% +$165 ﹤0.01% 1458
2025
Q4 		$108 Buy
+3
New +$92 ﹤0.01% 1674

Other funds holding INDV

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
OCM
Oaktree Capital Management Los Angeles, California $7.21B AUM 45.97% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $8.68B AUM 78.08% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Signature Equity Partners's INDV Position: Q2 2026 in Review

Signature Equity Partners held its Indivior Pharmaceuticals (INDV) position steady in Q2 2026 at 8 shares worth $328. The position accounts for ﹤0.01% of the portfolio, ranked #1465.

Signature Equity Partners first reported a position in INDV in Q4 2025 and has held it in 3 quarters since. 338 funds tracked by Wall St. Rank hold INDV as of Q2 2026.

  • Signature Equity Partners held 8 shares of Indivior Pharmaceuticals worth $328 as of Q2 2026.
  • Signature Equity Partners left its Indivior Pharmaceuticals share count unchanged in Q2 2026.
  • Indivior Pharmaceuticals made up ﹤0.01% of Signature Equity Partners's portfolio in Q2 2026, its #1465 holding.
  • Signature Equity Partners first reported a position in Indivior Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • 338 funds tracked by Wall St. Rank held Indivior Pharmaceuticals as of Q2 2026.

Based on Signature Equity Partners's 13F filing for Q2 2026, filed 30 Jul 2026.